SCHEMBL1582071

SCHEMBL1582071

CCOC(=O)C(=CCC(C)(C)C)c1ccc(SC)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.46
ALDH1A1 P00352 4/20 0.46
KDM4E B2RXH2 2/20 0.46
SMN1; SMN2 Q16637 4/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
LMNA P02545 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
TSHR P16473 2/20 0.41
POLB P06746 1/20 0.40
MAPK1 P28482 3/20 0.38
AKR1C3 P42330 3/20 0.37
AKR1C2 P52895 2/20 0.37
AKR1C1 Q04828 2/20 0.37
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
EPHX2 P34913 1/20 0.36
NR1H4 Q96RI1 1/20 0.36
PLK1 P53350 1/20 0.36
HRH2 P25021 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1582067 1.00 MAPT (0.46) MAPTALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL1582170 0.81 MAPT (0.46) MAPTALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL1582168 0.81 MAPT (0.46) MAPTALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL1581794 0.80 AKR1C3 (0.43) ALDH1A1AKR1C3
SCHEMBL1581792 0.80 AKR1C3 (0.43) ALDH1A1AKR1C3
SCHEMBL1581975 0.79 MAPT (0.44) MAPTALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL1581973 0.79 MAPT (0.44) MAPTALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL1582184 0.78 MAPT (0.48) MAPTALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL1581875 0.76 ALDH1A1 (0.42) MAPTALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL1581872 0.76 ALDH1A1 (0.42) MAPTALDH1A1KDM4ESMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1585739-B1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS LILLY CO ELI (US) 2011-04-20 EP disclosed
US-7576108-B2 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY 2006-05-25 US disclosed
EP-1585739-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2005-10-19 EP disclosed
WO-2004063179-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators GCK, GCKR, GALK1 MAPT 4102/4885ALDH1A1 510/4885KDM4E 2598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.